NSE ScannerBusiness Services · Miscellaneous Commercial Services · NSE: CONCORDBIO · data 2026-10-30
Concord Biotech Ltd.
In plain words
Price: 22.9% below its 52-week high of ₹1,615.
Delivery: 45.2% of traded shares were kept for delivery over the last 10 sessions, against 45.6% over the last 60.
Latest results: a net profit of ₹71 cr for the quarter ended Sept 2026 (+11.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,170 cr |
| Net profit (last 12 months) | ₹282 cr |
| Sales growth, 3 years (yearly) | 8.0% |
| Profit growth, 3 years (yearly) | 2.8% |
Latest results in brief (Q2 FY27)
Q2 FY27
Revenue: 309.07
Net Profit: 70.65
Operating Margin: 33.8
EPS: 6.65
Q2 FY27
राजस्व: 309.07
नेट लाभ: 70.65
परिचालन मार्जिन: 33.8
EPS: 6.65
Q2 FY27
મહેસૂલ: 309.07
નેટ લાભ: 70.65
કાર્યકારી માર્જિન: 33.8
EPS: 6.65
Written by AI from the filed numbers and checked against them. Not a recommendation.
Smart-money activity
16/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 44.1% over the last 20 sessions vs 41.8% in the 40 before (1.06x); shares delivered per day 0.68x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 4 schemes hold it, about ₹164 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 27 Oct 26Results Q2 FY27 results: profit +11.1% YoY -3.3% next session
- 31 Jul 26Results Q1 FY27 results: profit +32.8% YoY +6.4% next session
- 24 Jul 26Dividend Dividend ₹7.55 (ex-date) -1.0% next session
- 29 May 26Results Q4 FY26 results: profit −36.8% YoY -3.5% next session
- 11 Feb 26Results Q3 FY26 results: profit −15.1% YoY -4.2% next session
- 13 Nov 25Results Q2 FY26 results: profit −33.6% YoY +2.5% next session
- 8 Aug 25Results Q1 FY26 results: profit −26.1% YoY -1.7% next session
- 29 May 25Results Q4 FY25 results: profit +47.7% YoY +6.9% next session
- 14 Feb 25Results Q3 FY25 results: profit −2.1% YoY -20.3% next session
- 12 Nov 24Results Q2 FY25 results: profit +18.2% YoY -1.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹309 cr | ₹71 cr | +11.1% | 33.8% | 6.65 |
| Jun 2026 | ₹257 cr | ₹59 cr | +32.8% | 32.0% | 5.52 |
| Mar 2026 | ₹326 cr | ₹89 cr | -36.8% | 36.4% | 8.46 |
| Dec 2025 | ₹278 cr | ₹64 cr | -15.1% | 35.6% | 6.08 |
Common questions
What was Concord Biotech Ltd.'s latest quarterly profit?
Concord Biotech Ltd. reported a net profit of ₹71 cr for the quarter ended Sept 2026 (+11.1% on the same quarter a year earlier), on revenue of ₹309 cr.
Is Concord Biotech Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Concord Biotech Ltd.'s P/E ratio?
About 46.1, based on the last 12 months' earnings and a price of ₹1,245.6 (data 2026-10-30).
What is the 52-week high and low of Concord Biotech Ltd.?
The 52-week high is ₹1,615 and the 52-week low is ₹987.
Mutual funds holding Concord Biotech Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 4 schemes holding about ₹164 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 2.25% | ₹132 cr |
| SBI Balanced Hybrid Fund | SBI Mutual Fund | 0.83% | ₹16 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 0.17% | ₹16 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.34% | ₹0 cr |
Similar companies
International Gemological Institute Ltd (IGIL) · Choice International Limited (CHOICEIN) · Syngene International Ltd. (SYNGENE) · eClerx Services Limited (ECLERX) · Central Mine Planning & Design Institute Limited (CMPDI)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CONCORDBIO in NSE Scanner →